NHẬN XÉT MỘT SỐ ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ SỐNG THÊM BỆNH NHÂN UNG THƯ DẠ DÀY GIAI ĐOẠN IB – III HÓA TRỊ BỔ TRỢ PHÁC ĐỒ XELOX TẠI BỆNH VIỆN UNG BƯỚU NGHỆ AN

Abstract

Objectives: Describe some clinical, paraclinical characteristics and survival outcomes of gastric cancer patients stage IB - III adjuvant chemotherapy with XELOX regimen at Nghe An Oncology Hospital. Methods: Descriptive study with longitudinal follow-up on 64 patients diagnosed with stage IB - III gastric cancer receiving adjuvant chemotherapy with XELOX regimen at Nghe An Oncology Hospital from January 2016 to June 2020. Results: The male/female ratio is 2/1, the average age of the disease is 58.6 ± 7.3, the age group 50-59 has the highest rate of 42%, the most common tumor location is the pyloric antrum accounting for 71.9%. Most patients had less than 16 lymph nodes removed accounting for 53.1%, tumor invasion is mainly T4a accounting for 59.3%, N1 lymph node metastasis was the highest with 35.9%, the most common stage of the disease is IIIA accounting for 42.2%, tumor ≥ T3 with lymph node metastasis accounts for 77.3%, adenocarcinoma accounted for the highest rate with 67.2%. The disease-free and overall survival rates at 36 months were respectively 81.4% and 88.6%. Conclusion: The deeper the tumor invasion, the higher the risk of lymph node metastasis. XELOX regimen in adjuvant treatment of gastric cancer helps to achieve high disease-free and overall survival at 3 years in the study group of patients.